Curis Lifesciences Limited (NSE:CURIS)
India · Delayed Price · Currency is INR 165.70
+14.35 (9.48%)
At close: Sep 7, 2026
Curis Lifesciences Revenue
In the fiscal year ending March 31, 2026, Curis Lifesciences had annual revenue of 606.29M INR with 22.16% growth.
Revenue
606.29M
Revenue Growth
+22.16%
P/S Ratio
2.21
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 606.29M | 109.97M | 22.16% |
| Mar 31, 2025 | 496.32M | 140.77M | 39.59% |
| Mar 31, 2024 | 355.56M | 1.07M | 0.30% |
| Mar 31, 2023 | 354.49M | 117.04M | 49.29% |
| Mar 31, 2022 | 237.45M | 24.85M | 11.69% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Global Surfaces | 2.24B |
| DCG Cables & Wires | 1.63B |
| Aksh Optifibre | 1.50B |
| Aluwind Infra-Tech | 1.39B |
| Sheel Biotech | 1.10B |
| VijayPD Ceutical | 1.04B |
| Aesthetik Engineers | 781.21M |
| Striders Impex | 751.97M |